Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jeffrey Kellogg

Adult Medicine Shepherdstown, WV Medical Doctor

NPI 1861532350 CMS profile 356836

45 Maddex Dr, Shepherdstown, WV 25443

Open in the dashboard

General payments

$1,635

97 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jeffrey Kellogg of Shepherdstown, WV is reported in the CMS Open Payments database as having received $1,635 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Adult Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $28 2
2022 General $510 26
2021 General $253 18
2020 General $383 19
2019 General $460 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kellogg
  • Adult Medicine median
  • Middle half of Adult Medicine
  • National median

In program year 2025, general payments to Jeffrey Kellogg were reported at $0. Among 691 Adult Medicine profiles paid that year, the median was $151 and the middle half received between $51 and $528.

Show as a table
Year Jeffrey Kellogg Adult Medicine median Middle half National median
2019 $460 $140 $41–$517 $163
2020 $383 $107 $25–$378 $114
2021 $253 $136 $32–$529 $132
2022 $510 $138 $39–$492 $149
2023 $28 $155 $46–$483 $160
2024 $0 $153 $46–$554 $164
2025 $0 $151 $51–$528 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $531 22 payments
  2. Lilly USA, LLC $336 25 payments
  3. AstraZeneca Pharmaceuticals LP $207 13 payments
  4. Kowa Pharmaceuticals America, Inc. $89 6 payments
  5. AbbVie, Inc. $89 5 payments
  6. Janssen Pharmaceuticals, Inc $69 5 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $58 4 payments
  8. Pfizer Inc. $39 3 payments
  9. Sanofi-Aventis U.S. LLC $33 2 payments
  10. Allergan Inc. $29 2 payments
  11. Other $155 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,616 95 payments
  2. Education $19 2 payments
Products named General payments · program years 2019–2023
  1. Ozempic $418 20 payments
  2. RYBELSUS $350 17 payments
  3. JARDIANCE Diabetes $281 20 payments
  4. FARXIGA $193 12 payments
  5. TRULICITY $144 11 payments
  6. Livalo $89 6 payments
  7. XARELTO $69 5 payments
  8. INVOKANA $69 5 payments
  9. JARDIANCE Diabetes $58 4 payments
  10. UBRELVY $51 3 payments
  11. Other $634 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record